| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $202,086,092 ) (Continued on the next page) |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01MD019029 | The development a new Multidimensional and Multilevel Measure of Institutional and Economic Barriers for English and Spanish speaking populations | 000 | 4 | NIH | 4/14/2026 | $620,272 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01NS145443 | Mechanisms and intervention of cGAS signaling in brain trauma-induced neuroinflammation and neurodegeneration | 000 | 2 | NIH | 8/5/2026 | $640,343 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01HL180768 | Functional characterization of genes and genetic variants associated with hypoplastic heart syndrome in Drosophila | 000 | 2 | NIH | 6/24/2026 | $761,476 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R21CA302901 | Protein Degradation Strategies to Overcome Menin Drug Resistance in Acute Leukemias | 000 | 1 | NIH | 5/15/2026 | $399,829 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R21AG095506 | Instrumented brain organoids transplantation for chronic stroke treatment | 000 | 1 | NIH | 5/15/2026 | $649,688 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | UG1HD113162 | Resilient HIV Implementation Science with Sexual and Gender Minority Youths using Evidence (RISE) Clinical Research Center | 006 | 4 | NIH | 8/31/2026 | $59,004 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R25TW011804 | Strengthening Capacity in Health Research Ethics and Methodology in The Gambia | 000 | 5 | NIH | 6/24/2026 | $167,662 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | UG1HD113162 | Resilient HIV Implementation Science with Sexual and Gender Minority Youths using Evidence (RISE) Clinical Research Center | 005 | 4 | NIH | 8/24/2026 | $131,130 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | UG1HD113162 | Resilient HIV Implementation Science with Sexual and Gender Minority Youths using Evidence (RISE) Clinical Research Center | 003 | 4 | NIH | 8/4/2026 | $0 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | UG1HD113162 | Resilient HIV Implementation Science with Sexual and Gender Minority Youths using Evidence (RISE) Clinical Research Center | 003 | 4 | NIH | 8/4/2026 | $0 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | UG1HD113162 | Resilient HIV Implementation Science with Sexual and Gender Minority Youths using Evidence (RISE) Clinical Research Center | 003 | 4 | NIH | 8/4/2026 | $0 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R25TW011804 | Strengthening Capacity in Health Research Ethics and Methodology in The Gambia | 002 | 5 | NIH | 7/3/2026 | $69,324 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | UG1HD113162 | Resilient HIV Implementation Science with Sexual and Gender Minority Youths using Evidence (RISE) Clinical Research Center | 003 | 4 | NIH | 8/4/2026 | $0 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | UG1HD113162 | Resilient HIV Implementation Science with Sexual and Gender Minority Youths using Evidence (RISE) Clinical Research Center | 002 | 4 | NIH | 7/30/2026 | $50,000 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | T32GM159581 | Training Program in Cellular and Molecular Membrane Biology | 000 | 2 | NIH | 5/28/2026 | $421,217 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | UG1HD113162 | Resilient HIV Implementation Science with Sexual and Gender Minority Youths using Evidence (RISE) Clinical Research Center | 002 | 4 | NIH | 7/30/2026 | $66,666 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | UG1HD113162 | Resilient HIV Implementation Science with Sexual and Gender Minority Youths using Evidence (RISE) Clinical Research Center | 002 | 4 | NIH | 7/30/2026 | $150,000 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | UG1HD113162 | Resilient HIV Implementation Science with Sexual and Gender Minority Youths using Evidence (RISE) Clinical Research Center | 002 | 4 | NIH | 7/30/2026 | $378,595 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01DA061796 | Mechanistic Evaluation of Gabapentin and Opioid Polypharmacy | 000 | 1 | NIH | 5/28/2026 | $659,796 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01DA061796 | Mechanistic Evaluation of Gabapentin and Opioid Polypharmacy | 001 | 1 | NIH | 6/3/2026 | $0 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01NR021713 | Empowering Baltimore youth through applied research experiences to improve diet quality in older adults living in healthy food priority areas | 000 | 1 | NIH | 5/21/2026 | $2,160,854 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | K07AG090393 | Academic Leadership Award: Training Program in Gerontologic Biostatistics and Data Science | 000 | 1 | NIH | 9/7/2026 | $80,358 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AT013604 | Developing and Validating a Multi-Omic, Psychosocial, and Environmental Model of Individual Differences in Pain and Placebo Responses | 000 | 1 | NIH | 9/1/2026 | $4,929,839 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | K07AG090393 | Academic Leadership Award: Training Program in Gerontologic Biostatistics and Data Science | 000 | 1 | NIH | 9/7/2026 | $80,357 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R21DA065852 | Low-dose ketamine for the treatment of opioid use disorder | 000 | 1 | NIH | 9/17/2026 | $233,250 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R21AA033212 | Reverse-translational investigation of gut microbial contributions to alcohol sensitivity and tolerance. | 000 | 1 | NIH | 9/9/2026 | $408,188 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01MH139606 | Quantifying cerebellar multi-omic and synaptic features of autism spectrum disorders | 000 | 1 | NIH | 3/9/2026 | $762,566 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | T0856440 | Scholarships for Disadvantaged Students | 00 | 1 | HRSA | 9/23/2026 | $131,600 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01DK149875 | Regulation and Role of pDC in Immunopathogenesis of HBV/HIV co-Infection | 000 | 1 | NIH | 9/4/2026 | $617,553 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R21AI199182 | Evolution of Multi-Drug Resistance in Candida auris In Vitro and in Patients Undergoing Antifungal Treatment | 000 | 1 | NIH | 9/2/2026 | $233,250 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | U4R55855 | Pediatric Mental Health Care Access | 01 | 1 | HRSA | 9/17/2026 | $0 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | U4R55855 | Pediatric Mental Health Care Access | 00 | 1 | HRSA | 9/4/2026 | $445,000 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AI198756 | Culture-Independent Pathogen Identification Through Rapid Lipidomic Profiling | 000 | 1 | NIH | 9/8/2026 | $769,725 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AI201678 | Mycoplasma genitalium in Women: Natural History, Clinical Sequelae, and Host-Microbiome-Mediated Clearance | 000 | 1 | NIH | 9/17/2026 | $804,984 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01DK143590 | The Molecular Landscape of Liver Transplant Ischemia-Reperfusion Injury: Insights into Tissue Repair, Regeneration and Outcome Risk Stratification | 000 | 1 | NIH | 9/17/2026 | $772,331 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01CA309399 | The effects of time-restricted eating on fatigue and the frailty phenotype among people living with cancer | 000 | 1 | NIH | 9/14/2026 | $638,479 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R03CA304848 | High Throughput Profiling of the In Vivo Tumor Neo-antigen Specific Antibody Reactivity Landscape using PhIP-Seq | 000 | 1 | NIH | 9/22/2026 | $155,500 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R56DE035818 | New approach to improve therapeutics for advanced head and neck squamous cell cancer | 000 | 1 | NIH | 9/17/2026 | $521,524 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | K24AG098115 | Mentorship in Patient-Oriented Research to Improve Health of Older Adults with Diabetes | 000 | 1 | NIH | 9/2/2026 | $210,405 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R34AT013235 | Evaluating the feasibility and acceptability of expectation-optimized open-label placebo as an adjuvant treatment for chronic pain | 000 | 1 | NIH | 9/9/2026 | $692,332 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R21AI196307 | Modeling the Vaginal Microbiome: Predicting BV Recurrence and Identifying Preventative Targets | 000 | 1 | NIH | 4/6/2026 | $427,625 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AT013426 | Green Light Therapy and Brain Mechanisms of Pain and Anxiety | 000 | 2 | NIH | 6/18/2026 | $200,000 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | K01AI196239 | Host-pathogen-microbiome interactions in Mycoplasma genitalium infection, pathology, and treatment: experiments in a 3D organotypic cervical epithelium model to strengthen clinical guidelines | 000 | 1 | NIH | 4/24/2026 | $155,893 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R21AI187784 | Plant-derived nanoparticles as a sepsis therapy | 000 | 1 | NIH | 6/26/2026 | $233,250 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01AT013426 | Green Light Therapy and Brain Mechanisms of Pain and Anxiety | 000 | 2 | NIH | 6/18/2026 | $540,090 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | K12CA301384 | Advancing Oncologic Research Communities in Health Equity (ARCH) K12 Program | 000 | 2 | NIH | 8/28/2026 | $811,194 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | K23AI189218 | The Role of Sex-Hormones in Anal Human Papilloma Virus Persistence (HPV) and Systemic and Mucosal Immunity in people with or at risk for HIV | 001 | 2 | NIH | 8/27/2026 | $148,273 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R01CA315681 | Mechanisms of Anti-Estrogen Therapy-Induced Pain in Breast Cancer | 000 | 1 | NIH | 8/11/2026 | $598,422 |
| | 2026 | 2026 | UNIVERSITY OF MARYLAND, BALTIMORE | 220 ARCH ST OFC LEVEL2 | BALTIMORE | MD | 21201-1531 | BALTIMORE CITY | USA | R34AI195140 | Planning grant to evaluate the use of pentavalent meningococcal vaccine in pregnant women in sub-Saharan Africa | 000 | 1 | NIH | 8/20/2026 | $233,250 |
|
